CAR-T cells are genetically engineered autologous T lymphocytes designed to express a chimeric antigen receptor that combines (1) an extracellular single-chain variable fragment (scFv) targeting a tumor-associated antigen (e.g., CD19), (2) a transmembrane domain coupled with the CD3ζ signaling module, and (3) one or more co-stimulatory domains (e.g., CD28 or 4-1BB) [24]. This evidence concerns the gene CD19 and neoplasm.